AstraZeneca PLC (AZN)vsTotalEnergies SE ADR (TTE)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
TTE
TotalEnergies SE ADR
$89.40
+0.78%
ENERGY · Cap: $195.51B
Smart Verdict
WallStSmart Research — data-driven comparison
TotalEnergies SE ADR generates 204% more annual revenue ($183.96B vs $60.44B). AZN leads profitability with a 17.2% profit margin vs 8.2%. TTE appears more attractively valued with a PEG of 0.72. TTE earns a higher WallStSmart Score of 72/100 (B).
AZN
Buy64
out of 100
Grade: C+
TTE
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for TTE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 57.1% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.3%
Areas to Watch
Moderate valuation
Distress zone — elevated risk
3.4% revenue growth
Grey zone — moderate risk
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TTE
The strongest argument for TTE centers on EPS Growth, Market Cap, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TTE
The primary concerns for TTE are Revenue Growth, Altman Z-Score, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while TTE is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
TTE scores higher overall (72/100 vs 64/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TotalEnergies SE ADR
ENERGY · OIL & GAS INTEGRATED · USA
TotalEnergies SE is a global integrated oil and gas company. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?